AbbVie (ABBV) February weekly 165 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
February 5, 2024 5:58 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a Buy rating.
The analyst comments "4Q23 results and management's commentary on the FY24 and longer-term outlook strengthen our confidence in the potential for ABBV shares to continue to outperform. Across the company's Immunology... More
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
February 2, 2024 8:37 AM ESTAbbVie (NYSE: ABBV) shares edged around 1% higher early Friday after the company reported earnings before the open, topping fourth-quarter profit and revenue expectations.
The American pharmaceutical company reported fourth-quarter adjusted earnings of $2.79 per share, $0.02 better than the analyst estimate of $2.77. Meanwhile, revenue... More
